Eventide Gilead Fund Listed in Money Magazine’s 2015 Investor’s Guide
The Eventide Gilead Fund has been featured in Money Magazine‘s 2015 Investor’s Guide, which lists mutual funds that have performed well in their categories over the past one and five years. According to Money‘s analysis, “A boom in health care and transportation costs—not just in 2014, but over the past five years—propelled many of the highest-performing funds that invest in midsize companies.”
Past performance does not guarantee future results
Mutual Funds involve risk including the possible loss of principal. The fund can invest in smaller-sized companies which may experience higher failure rates than larger companies normally have a lower trading volume than larger companies. The Fund’s ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.
Investors should carefully consider the investment objectives, risks, charges and expenses of the Eventide Gilead Fund. This and other important information about the Fund is contained in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). The prospectus should be read carefully before investing. The Eventide Gilead Fund is distributed by Northern Lights Distributors, LLC member FINRA.